Improve your knowledge of Radiation Oncology through this program, where you will find the best teaching material with real clinical cases. Learn about the latest advances in the field to be able to conduct excellent medical practice"

Given the growing number of publications in this field, it is difficult to keep up to date with the best scientific evidence continuously over time. The objective of this Professional master’s degree is to fill the gap for professionals interested in the area, seeking to update and improve clinical practice and encourage research into the topics that are covered. 

The aforementioned technological advances, although decisive, are not in themselves the sole focus of Radiation Oncology. Technology is a complement to medicine and, above all, a tool for cancer treatment, and must be accompanied by careful clinical assessment based on clinical and biological knowledge of cancer. 

As a clinician, the radiation oncologist's role revolves around patient contact, but requires theoretical and practical knowledge and skills for the prescription and application of radiotherapy treatment. Hence, updating this knowledge is key to gaining a better view of each individual patient. 

The medical sciences, and therefore oncology, are constantly growing bodies of knowledge thanks to the information obtained through basic and translational research; the latter being a powerful flow of knowledge coming mainly from molecular biology to the clinic, changing our understanding of cancer, not only its diagnosis but treatment of the disease at all stages, with the ultimate goal of improving medical care. This Professional master’s degree offers the opportunity to complement specialist knowledge with a detailed and updated review of the most relevant technological and conceptual advances in the field. 

Update your knowledge through the Professional master’s degree in Radiation Oncology" 

This Professional master’s degree in Radiation Oncology contains the most complete and up-to-date scientific program on the market. Its most notable features are: 

• More than 75 clinical cases presented by experts in Radiation Oncology
• Graphic, schematic, and practical contents which provide scientific and practical information on the disciplines that are essential for professional practice
• Diagnostic-therapeutic developments in the assessment, diagnosis, and intervention for Radiation Oncology 
• Practical exercises where a self-evaluation process can be carried out to improve learning
• Clinical and diagnostic imaging tests iconography 
• An algorithm-based interactive learning system for decision-making in the clinical situations presented throughout the course
• A special emphasis on evidence-based medicine and research methodologies in Radiation Oncology
• All of this will be complemented by theoretical lessons, questions to the expert, debate forums on controversial topics, and assignments for individual reflection
• Content that is accessible from any fixed or portable device with an internet connection

This Professional master’s degree is the best investment you can make when selecting a refresher program, for two reasons: in addition to updating your knowledge of Radiation Oncology, you will obtain a qualification from TECH Global University"

The teaching staff of the program includes professionals belonging to the field of Radiation Oncology who contribute their professional experience into this course, as well as renowned specialists from leading scientific societies. 

Thanks to its multimedia content developed with the latest educational technology, it will allow the professional a situated and contextual learning, that is to say, a simulated environment that will provide an immersive learning programmed so students learn from real situations. 

This program is designed around Problem-Based Learning, whereby the physician must try to solve the different professional practice situations that arise during the course. For this purpose, the professional will be assisted by an innovative interactive video system created by renowned and experienced experts. 

Increase your confidence in decision-making by updating your knowledge through this Professional master’s degree"

Make the most of this opportunity to learn about the latest advances in Radiation Oncology and improve patient care"

The syllabus has been designed by a team of professionals from leading hospitals and universities, who, aware of the current importance of professional education to be able to intervene in the diagnosis and treatment of cancer through the use of radiotherapy, have put together the most complete and innovative compendium of contents on the market. All of this reinforces TECH's commitment to new educational methodologies and high-quality teaching. 

This Professional master’s degree in Radiation Oncology contains the most complete and up-to-date scientific program on the market"

Module 1. Principles of Radiotherapy: Radiobiology

1.1. Biological Effects of Ionizing Radiation

1.1.1. DNA Damage
1.1.2. Non-Clonal Effects

1.2. Dose Fractionation

1.2.1. Linear-Quadratic Model
1.2.2. Time Factor in Radiotherapy
1.2.3. Altered Subdivisions

1.3. Oxygen Effect and Tumor Hypoxia
1.4. Radiobiology of Brachytherapy
1.5. Effects of Irradiation on Healthy Tissues
1.6. Combination of Irradiation with Drugs
1.7. Predictive Assays of Response to Radiotherapy
1.8. Radiobiology of Re-Irradiation
1.9. Effects of Irradiation on the Embryo and Fetus
1.10. Radiation-Induced Carcinogenesis

Module 2. Update on Radiotherapy for Central Nervous System Tumors (Adults) 

2.1. Low-Grade Gliomas
2.2. High-Grade Gliomas
2.3. Benign Brain Tumors
2.3.1. Meningiomas

2.3.2. Vestibular Schwannoma
2.3.3. Neurinoma

2.4. Pituitary Tumors

2.4.1. Non-Functioning Adenomas
2.4.2. Prolactinoma
2.4.3. GH-Producing Adenoma
2.4.4. Cushing's Disease
2.4.5. GnRH TSH Secreting Adenomas 
2.4.6. Pituitary Carcinomas

2.5. Spinal Cord Tumors

2.5.1. Astrocytoma
2.5.2. Ependymoma
2.5.3. Meningioma
2.5.4. Chordoma
2.5.5. Chondrosarcoma
2.5.6. Miscellaneous Spinal Tumors
2.5.7. Spinal Cord Compression
2.5.8. Medulloblastoma
2.5.9. Craniopharyngioma 

2.6. Orbital, Ocular and Optic Nerve Tumors 

2.6.1. Rhabdomyosarcoma
2.6.2. Pineal Gland Tumors
2.6.3. Orbital Lymphoma
2.6.4. Ocular Melanoma
2.6.5. Ocular Metastases
2.6.5. Optic Nerve Glioma
2.6.6. Optic Nerve Meningioma

2.7. Primary cerebral Lymphoma
2.8. Cerebral Metastases
2.9. Arteriovenous Malformations

Module 3. Update on Radiotherapy for ENT Tumors

3.1. Oral Cavity

3.1.1. Lip
3.1.2. Tongue
3.1.3. Floor of Mouth
3.1.4. Gum
3.1.5. Hard Palate
3.1.6. Retromolar Trigone
3.1.7. Jugal Mucosa

3.2. Oropharynx

3.2.1. Soft Palate
3.2.2. Tonsils
3.2.3. Oropharyngeal Wall
3.2.4. Base of the Tongue

3.3. Nasopharynx
3.4. Larynx and Hypopharynx

3.4.1. Larynx.
3.4.1.1. Glottis

3.4.1.2. Supraglottis
3.4.1.3. Subglottis

3.4.2. Hypopharynx

3.4.2.1. Pyriform Sinus
3.4.2.2. Hypopharyngeal Wall
3.4.2.3. Post Cricoid Carcinoma

3.4.3. Epidermoid Carcinoma Variants

3.4.3.1. Verrucous Carcinoma
3.4.3.2. Sarcomatoid Carcinoma
3.4.3.3. Neuroendocrine Carcinoma

3.5. Nasal and Paranasal Sinuses

3.5.1. Nasal Vestibule
3.5.2. Nasal Cavity and Ethmoid Sinus
3.5.3. Maxillary Sinus

3.6. Salivary Glands
3.7. Thyroid

3.7.1. Papillary Carcinoma
3.7.2. Follicular Carcinoma
3.7.3. Spinal Cord Carcinoma
3.7.4. Anaplastic Carcinoma
3.7.5. Primary Thyroid Lymphoma

3.8. Cervical Lymph Node Metastases of Unknown Origin

Module 4. Update on Radiotherapy for Thoracic Tumors 

4.1. Non-Small Cell Lung Cancer

4.1.1. General Information on Non-Small Cell Lung Cancer
4.1.2. Early-Stage Radiotherapy 
4.1.3. Radical Radiotherapy in Locally Advanced Stages
4.1.4. Postoperative Radiotherapy 
4.1.5. Palliative Radiotherapy 

4.2. Small Cell Lung Cancer

4.2.1. General Information on Small Cell Lung Cancer
4.2.2. Radiotherapy for Disease Limited to the Thorax
4.2.3. Radiotherapy in Extended Disease
4.2.4. Prophylactic Cranial Irradiation
4.2.5. Palliative Radiotherapy 

4.3. Uncommon Thoracic Tumors

4.3.1. Thymic Tumors

4.3.1.1. General Information on Thymic Tumors
4.3.1.2. Radiotherapy for Thymic Carcinoma
4.3.1.3. Radiotherapy for Thymomas

4.3.2. Carcinoid Lung Tumors

4.3.2.1. General Information on Carcinoid Lung Tumors
4.3.2.2. Radiotherapy for Carcinoid Lung Tumors

4.3.3. Mesothelioma

4.3.3.1. General Information on Mesotheliomas
4.3.3.2. Radiotherapy for Mesotheliomas (Adjuvant, Radical, Palliative)

4.4. Primary Cardiac Tumors

4.4.1. General Information on Cardiac Tumors
4.4.2. Radiotherapy for Cardiac Tumors

4.5. Pulmonary Metastases

4.5.1. General Information on Pulmonary Metastases
4.5.2. Definition of Oligometastatic Lung Status
4.5.3. Radiotherapy for Pulmonary Oligometastases

Module 5. Update on Radiotherapy for Breast Tumors

5.1. Introduction to Infiltrating Breast Cancer

5.1.1. Etiology
5.1.2. Epidemiology
5.1.3. Advantages of Screening: Overdiagnosis and Cost Overruns
5.1.4. Clinical and Pathological Staging
5.1.5. Radiological Diagnosis
5.1.6. Histological Diagnosis: Molecular Subtypes
5.1.7. Prognosis

5.2. General Information on Radiotherapy for Breast Cancer

5.2.1. Simulation Process: Positioning and Immobilization Systems
5.2.2. Image Acquisition and Volume Delimitation
5.2.3. Techniques: 3D-CRT, Evidence of IMRT/VMAT Use in Breast Cancer
5.2.4. Dosage, Fractionation and Constraints
5.2.5. Breath Hold
5.2.6. Image-Guided Radiation Therapy (IGRT)
5.2.7. Radiotherapy in the Presence of Cardiac Devices

5.3. Indications for Radiotherapy on the Breast after Conservative Treatment for Infiltrating Breast Cancer

5.3.1. Exclusive Preoperative Radiotherapy
5.3.2. Adjuvant Radiotherapy after Conservative Surgery and/or Primary Systemic Therapy
5.3.3. Evidence in Subdivisions
5.3.4. Is Conservative Treatment Better than a Mastectomy?
5.3.5. Radiotherapy according to Molecular Subtype?

5.4. Indications for Radiotherapy after Mastectomy for Infiltrating Breast Cancer

5.4.1. Post-Mastectomy Radiotherapy According to Type of Surgery
5.4.2. Post-Mastectomy Radiotherapy in N0 Cancer: Radiotherapy According to Molecular Subtype?
5.4.3. Post-Mastectomy Radiotherapy in Complete Response after Primary Systemic Treatment
5.4.4. Rib Wall Hypofractionation
5.4.5. Inflammatory Carcinoma

5.5. Radiotherapy and Post-Mastectomy Breast Reconstruction

5.5.1. Types of Surgery (Radical Mastectomy, Skin Sparing, CAP Preservation, etc.)
5.5.2. Types of Reconstruction and Advantages/Disadvantages of RT before or after RT
5.5.3. Hypofractionation in Patients Following Breast Reconstruction Surgery

5.6. Axilla Management for the Radiation Oncologist: Radiotherapy Indication in Chains

5.6.1. Nodal Staging in Diagnosis and Sentinel Node Detection Methods
5.6.2. RT after Lymphadenectomy and after Positive Sentinel Gland at the Time of Surgery
5.6.3. RT after Sentinel Node before/after Primary Systemic Therapy
5.6.4. Hypofractionation in Chains
5.6.5. Risk of Plexopathy

5.7. Boost: Indications and Radiotherapy Techniques

5.7.1. Justification for the Implementation of Boost
5.7.2. Indications after Conservative Surgery, Oncoplastic Surgery and Mastectomy
5.7.3. External Radiotherapy Techniques: Simultaneous Integrated Boost (SIB)
5.7.4. Brachytherapy
5.7.5. Intraoperative Radiotherapy (IORT)

5.8. Partial Breast Irradiation: Indications and Radiotherapy Techniques

5.8.1. Justification for Performing Magnetic Particle Imaging (MPI)
5.8.2. Preoperative Radiotherapy
5.8.3. External RT: 3D-CRT. Intensity-Modulated Radiation Therapy (IMRT). SBRT
5.8.4. Brachytherapy
5.8.5. Intraoperative Radiotherapy (IORT)

5.9. Radiotherapy in Non-Invasive Carcinoma

5.9.1. Introduction

5.9.1.1. Etiology
5.9.1.2. Epidemiology
5.9.1.3. Advantages of Screening

5.9.2. Indications after Conservative Surgery and Evidence after Mastectomy
5.9.3. Genetic Platform in Ductal Carcinoma In Situ (DCIS)

5.10. Radiotherapy and Systemic Treatment

5.10.1. Concomitant Radiotherapy/Chemotherapy

5.10.1.1. Neoadjuvant
5.10.1.2. Inoperable
5.10.1.3. Adjuvant

5.10.2. Sequence with Systemic Treatment. Is it Possible to Administer Radiotherapy Prior to Chemotherapy after Surgery?
5.10.3. Radiotherapy and Hormonal Therapy (Tamoxifen, Aromatase Inhibitors): Evidence for their Sequential Administration: Is Concomitance Better?
5.10.4. Chemotherapy Followed by Radiotherapy without Surgery?
5.10.5. Association between Radiotherapy and Anti-Her2 Teatment (Trastuzumab and Pertuzumab)
5.10.6. Possible Toxicities of the Association

5.11. Evaluation of the Response: Monitoring Treatment of Locoregional Recurrences: Re-Irradiation
5.12. Locoregional Radiotherapy in Metastatic Breast Cancer: Treatment of Oligometastases. Stereotactic Body Radiotherapy (SBRT). Radiotherapy and Immunotherapy.
5.13. Male Breast Cancer and Other Breast Tumors: Paget's Disease; Phyllodes; Primary Lymphoma

Module 6. Update on Radiotherapy for Digestive Tumors

6.1. Esophageal Tumors

6.1.1. General Information on Esophageal Tumors
6.1.2. Radical Treatment of Cervical Esophageal Cancer
6.1.3. Radical Treatment of Thoracic Esophageal Cancer
6.1.4. Adjuvant Treatment of Thoracic Esophageal Cancer
6.1.5. Palliative Radiotherapy 

6.2. Gastric and Gastroesophageal Junction Tumors

6.2.1. General Information about Gastric and Gastroesophageal Junction Cancer
6.2.2. Neoadjuvant Radiochemotherapy
6.2.3. Adjuvant Radiochemotherapy
6.2.4. Role of Radiotherapy in the Context of Perioperative Chemotherapy
6.2.5. Radical Radiochemotherapy
6.2.6. Palliative Radiotherapy 

6.3. Pancreatic Tumors

6.3.1. Overview of Pancreatic Cancer
6.3.2. Role of Radiotherapy in Resectable Tumors
6.3.3. Role of Radiotherapy in Potentially Resectable Tumors (Borderline)
6.3.4. Role of Radiotherapy in Unresectable Tumors
6.3.5. Role of Radiotherapy in Inoperable Tumors
6.3.6. Palliative Radiotherapy 

6.4. Hepatobiliary Tumors

6.4.1. General Information on Hepatobiliary Tumors
6.4.2. Hepatocellular Carcinoma
6.4.3. Gallbladder Cancer
6.4.4. Cholangiocarcinoma
6.4.5. Liver Metastases

6.5. Colorectal Cancer

6.5.1. General Information on Colorectal Tumors
6.5.2. Neoadjuvant Treatment in Rectal Cancer
6.5.3. Adjuvant Treatment in Rectal Cancer
6.5.4. Radical Treatment in Rectal Cancer
6.5.5. Radiotherapy in Recurrences: Re-Irradiation
6.5.6. Role of Radiotherapy in Colon Cancer
6.5.7. Palliative Radiotherapy 

6.6. Anal Canal and Perianal Skin Cancer

6.6.1. Overview of Anal Canal and Perianal Skin Cancer
6.6.2. Role of Radiotherapy in Early Tumors and Carcinoma In Situ
6.6.3. Radical Treatment of Locally Advanced Tumors
6.6.4. Palliative Radiotherapy 

Module 7. Update on Radiotherapy for Gynecologic Tumors

7.1. Endometrial Cancer

7.1.1. Epidemiological Aspects
7.1.2. Risk Factors
7.1.3. Anatomy Recap
7.1.4. Histological Type
7.1.5. Dissemination Pathways
7.1.6. Classification
7.1.7. Prognostic Factors
7.1.8. Surgical Management
7.1.9. Adjuvant Early-Stage Radiotherapy 
7.1.10. Advanced Disease
7.1.11. Local, Regional, Distant Recurrence
7.1.12. Monitoring

7.2. Uterine Sarcomas

7.2.1. Epidemiological Aspects
7.2.2. Risk Factors
7.2.3. Anatomy Recap
7.2.4. Histological Type
7.2.5. Dissemination Pathways
7.2.6. Classification
7.2.7. Prognostic Factors
7.2.8. Surgical Management
7.2.9. Adjuvant Early-Stage Radiotherapy 
7.2.10. Advanced Disease
7.2.11. Local, Regional, Distant Recurrence
7.2.12. Monitoring

7.3. Cervical Cancer

7.3.1. Epidemiological Aspects
7.3.2. Risk Factors
7.3.3. Anatomy Recap
7.3.4. Histological Type
7.3.5. Dissemination Pathways
7.3.6. Classification
7.3.7. Prognostic Factors
7.3.8. Surgical Management
7.3.9. Adjuvant Early-Stage Radiotherapy 
7.3.10. Advanced Disease
7.3.11. Local, Regional, Distant Recurrence
7.3.12. Monitoring

7.4. Vulvar Cancer

7.4.1. Epidemiological Aspects
7.4.2. Risk Factors
7.4.3. Anatomy Recap
7.4.4. Histological Type
7.4.5. Dissemination Pathways
7.4.6. Classification
7.4.7. Prognostic Factors
7.4.8. Surgical Management
7.4.9. Adjuvant Early-Stage Radiotherapy 
7.4.10. Advanced Disease
7.4.11. Local, Regional, Distant Recurrence
7.4.12. Monitoring

7.5. Vaginal Cancer

7.5.1. Epidemiological Aspects
7.5.2. Risk Factors
7.5.3. Anatomy Recap
7.5.4. Histological Type
7.5.5. Dissemination Pathways
7.5.6. Classification
7.5.7. Prognostic Factors
7.5.8. Surgical Management
7.5.9. Adjuvant Early-Stage Radiotherapy 
7.5.10. Advanced Disease
7.5.11. Local, Regional, Distant Recurrence
7.5.12. Monitoring

7.6. Fallopian Tube and Ovarian Cancer

7.6.1. Epidemiological Aspects
7.6.2. Risk Factors
7.6.3. Anatomy Recap.
7.6.4. Histological Type
7.6.5. Dissemination Pathways
7.6.6. Classification
7.6.7. Prognostic Factors
7.6.8. Surgical Management
7.6.9. Adjuvant Early-Stage Radiotherapy 
7.6.10. Advanced Disease
7.6.11. Local, Regional, Distant Recurrence
7.6.12. Monitoring

Module 8. Update on Radiotherapy for Prostate and Other Urologic Tumors

8.1. Prostate Cancer

8.1.1. Low-Risk
8.1.2. Intermediate Risk

8.1.2.1. Definition of Intermediate Risk Prostate Cancer
8.1.2.2. Subclassification of Intermediate Risk Prostate Cancer

8.1.2.2.1. Importance of Gleason 7

8.1.2.3. Diagnosis and Extension Study
8.1.2.4. Treatment

8.1.2.4.1. Active Surveillance
8.1.2.4.2. Radical Prostatectomy
8.1.2.4.3. Radiotherapy: Techniques and Requirements

8.1.2.4.3.1. Role of External Radiation Therapy
8.1.2.4.3.2. The Role of Brachytherapy
8.1.2.4.3.3. The Role of Stereotactic Body Radiotherapy SBRT
8.1.2.4.3.4. Combined Treatments

8.1.2.4.4. Hormone Therapy: When and How Much?
8.1.2.4.5. The Best Option for Each Patient

8.1.2.5. Monitoring
8.1.2.6. Conclusions

8.1.3. High-Risk
8.1.4. Local and/or Distant Relapse Treatment

8.1.4.1. Treatment of Local Relapse

8.1.4.1.1. After Prostatectomy
8.1.4.1.2. After Radiotherapy

8.1.4.1.2.1. Rescue Surgery
8.1.4.1.2.2. Rescue Cryotherapy
8.1.4.1.2.3. Rescue Brachytherapy
8.1.4.1.2.4. High-Intensity Focused Ultrasound (HIFU)
8.1.4.1.2.5. Intermittent Hormone Rescue

8.1.4.2. Treatment of Distant Relapse

8.1.4.2.1. Metastatic Patient
8.1.4.2.2. Oligorecurrent Patient

8.1.4.2.2.1. Hormonal Treatment
8.1.4.2.2.2. Surgical Management
8.1.4.2.2.3. SBRT Treatment

8.2. Preoperative and Postoperative Radiotherapy in Bladder Cancer

8.2.1. Introduction
8.2.2. Preoperative Radiotherapy

8.2.2.1. Bibliographic Review
8.2.2.2. Indications

8.2.3. Postoperative Radiotherapy

8.2.3.1. Bibliographic Review
8.2.3.2. Indications

8.2.4. Organ Conservative Treatment

8.3. Testicular Tumors

8.3.1. Introduction
8.3.2. Histological Type
8.3.3. TNM Classification and Prognostic Groups
8.3.4. Germinal Tumors: Treatment According to Stage and Prognostic Group

8.3.4.1. Seminoma
8.3.4.2. Non-Seminoma

8.3.5. Chemotherapy and Radiotherapy Toxicity
8.3.6. Secondary Neoplasms
8.3.7. Non-Germ Cell Tumors

8.4. Renal, Ureteral, and Urethral Tumors

8.4.1. Renal Tumors

8.4.1.1. Clinical Presentation
8.4.1.2. Diagnosis
8.4.1.3. Localized Disease Treatment
8.4.1.4. Advanced Disease Treatment

8.4.2. Urethral Tumors

8.4.2.1. Clinical Presentation: Men vs. Women
8.4.2.2. Diagnosis
8.4.2.3. Treatment

8.4.3. Ureter and Renal Pelvis Tumors

8.4.3.1. Risk Factors
8.4.3.2. Presentation: Primary Tumor–Metastasis
8.4.3.3. Symptoms/Clinical
8.4.3.4. Diagnosis
8.4.3.5. Localized Disease Treatment
8.4.3.6. Advanced Disease Treatment

8.5. Penile Cancer

8.5.1. Adjuvant Treatment
8.5.2. Radical Treatment

8.6. Treatment of Adrenal Metastases

8.6.1. Introduction
8.6.2. Surgery
8.6.3. SBRT

Module 9. Update on Radiotherapy for Low Incidence and Miscellaneous Tumors

9.1. Orbital and Ocular Tumors

9.1.1. Orbital Tumors

9.1.1.1. Rhabdomyosarcoma
9.1.1.2. Lacrimal Gland Tumors
9.1.1.3. Orbital Metastases
9.1.1.4. Orbital Pseudotumor
9.1.1.5. Graves-Basedow Ophthalmopathy

9.1.2. Tumors and Ocular Pathology

9.1.2.1. Choroidal Melanoma
9.1.2.2. Choroidal Metastasis
9.1.2.3. Primary Ocular Lymphoma
9.1.2.4. Pterygium
9.1.2.5. Macular Degeneration
9.1.2.6. Choroidal Hemangioma

9.2. Cutaneous Tumors

9.2.1. Melanoma
9.2.2. Non-Melanoma Skin Tumors

9.2.2.1. Basal Cell Carcinoma
9.2.2.2. Squamous Cell Carcinoma
9.2.2.3. Merkel Cells Carcinoma
9.2.2.4. Adnexal Carcinomas

9.3. Soft Tissue Sarcomas and Bone Tumors

9.3.1. Soft Tissue Sarcomas of the Extremities and Trunk
9.3.2. Retroperitoneal and Pelvic Sarcomas
9.3.3. Head and Neck Sarcomas
9.3.4. Dermatofibrosarcoma Protuberans
9.3.5. Desmoid Tumor
9.3.6. Bone Sarcomas

9.3.6.1. Ewing Sarcoma
9.3.6.2. Osteosarcoma
9.3.6.3. Chondrosarcoma
9.3.6.4. Chordoma

9.4. Hematological Tumors and Associated Techniques

9.4.1. Hodgkin's Lymphoma
9.4.2. Non-Hodgkin's Lymphoma
9.4.3. Multiple Myeloma
9.4.4. Plasmacytoma
9.4.5. Mycosis Fungoides
9.4.6. Kaposi's Sarcoma
9.4.7. Total Body Irradiation, Total Nodal Irradiation

9.5. Pediatric Tumors

9.5.1. Central Nervous System Tumors
9.5.2. Soft Tissue Sarcomas
9.5.3. Bone Sarcomas
9.5.4. Wilms Tumor
9.5.5. Retinoblastoma
9.5.6. Neuroblastoma
9.5.7. Leukemias and Lymphomas

9.6. Benign Pathology

9.6.1. Benign Joint and Tendon Diseases
9.6.2. Benign Connective and Skin Diseases

9.6.2.1. Keloids
9.6.2.2. Plantar Fasciitis
9.6.2.3. Gynecomastia

9.6.3. Benign Bone Tissue Diseases

9.6.3.1. Heterotopic Ossification
9.6.3.2. Vertebral Hemangiomas
9.6.3.3. Pigmented Villonodular Synovitis
9.6.3.4. Aneurysmal Bone Cyst

Module 10. Pain and Nutrition in Radiation Oncology

10.1. General Information on Oncologic Pain

10.1.1. Epidemiology
10.1.2. Prevalence
10.1.3. Impact of Pain
10.1.4. Multidimensional Concept of Cancer Pain

10.2. Characterization of Pain

10.2.1. Types of Oncologic Pain
10.2.2. Evaluation of Oncologic Pain
10.2.3. Prognosis of Pain
10.2.4. Classification
10.2.5. Diagnostic Algorithm

10.3. General Principles of Pharmacological Treatment
10.4. General Principles of Radiotherapy 

10.4.1. External Radiotherapy
10.4.2. Dosages and Fractions

10.5. Bisphosphonates
10.6. Radiopharmaceuticals in the Management of Metastatic Bone Pain
10.7. Pain in Long-Term Survivors
10.8. Nutrition and Cancer

10.8.1. Concept of Malnutrition
10.8.2. Prevalence of Malnutrition
10.8.3. Causes and Consequences of Malnutrition in Oncology Patients
10.8.4. Mortality and Survival
10.8.5. Nutritional Risk Factors in Oncology Patients
10.8.6. Objectives of Nutritional Support

10.9. Cachexia
10.10. Initial Nutritional Assessment in a Radiation Oncology Service

10.10.1. Diagnostic Algorithm
10.10.2. Specific Treatment
10.10.3. General Dietary Recommendations
10.10.4. Specific Individualized Recommendations

10.11. Nutritional Assessment During Monitoring in a Radiation Oncology Service

A unique, key and decisive educational experience to boost your professional development”